Study will evaluate the safety, tolerability and pharmacokinetics (PK) of OCT-980 in healthy volunteers
Initiation of the study marks Octant’s transition to a clinical-stage company
Conor J. Howard, Nathan S. Abell, Robert Warneford-Thomson, Eden Mahdavi, Carmen Resnick, Alan Su, Nabil Mohammed, Erin M. Thompson, Emily Holzinger, Katrina Catalano, Stephen C.Wilson, Joseph C. Maranville, Payal R. Sheth, Robert M. Plenge, Sriram Kosuri, Diane E. Dickel